Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons.

Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF, Maidment NT, Levine MS, Shen J.

J Biol Chem. 2003 Oct 31;278(44):43628-35. Epub 2003 Aug 20.

2.

Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.

Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, Chesselet MF, Yang XW.

J Neurosci. 2009 Feb 18;29(7):1962-76. doi: 10.1523/JNEUROSCI.5351-08.2009.

3.

Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.

Hennis MR, Marvin MA, Taylor CM 2nd, Goldberg MS.

Neurobiol Dis. 2014 Feb;62:113-23. doi: 10.1016/j.nbd.2013.09.009. Epub 2013 Sep 26.

4.

rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.

Manfredsson FP, Burger C, Sullivan LF, Muzyczka N, Lewin AS, Mandel RJ.

Exp Neurol. 2007 Oct;207(2):289-301. Epub 2007 Jul 10.

PMID:
17678648
5.

Behavioral and neurotransmitter abnormalities in mice deficient for Parkin, DJ-1 and superoxide dismutase.

Hennis MR, Seamans KW, Marvin MA, Casey BH, Goldberg MS.

PLoS One. 2013 Dec 26;8(12):e84894. doi: 10.1371/journal.pone.0084894. eCollection 2013.

6.

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, Iwatsubo T, Aebischer P.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17510-5. Epub 2004 Dec 2.

7.

Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons.

Son JH, Kawamata H, Yoo MS, Kim DJ, Lee YK, Kim S, Dawson TM, Zhang H, Sulzer D, Yang L, Beal MF, Degiorgio LA, Chun HS, Baker H, Peng C.

J Neurochem. 2005 Aug;94(4):1040-53.

8.

Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease.

Dusonchet J, Bensadoun JC, Schneider BL, Aebischer P.

Neurobiol Dis. 2009 Jul;35(1):32-41. doi: 10.1016/j.nbd.2009.03.013. Epub 2009 Apr 5.

PMID:
19348945
9.

Parkin deficiency increases vulnerability to inflammation-related nigral degeneration.

Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, Marvin M, Hartley M, Treviño I, O'Brien DE, Casey B, Goldberg MS, Tansey MG.

J Neurosci. 2008 Oct 22;28(43):10825-34. doi: 10.1523/JNEUROSCI.3001-08.2008.

10.

Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice.

Kitada T, Pisani A, Karouani M, Haburcak M, Martella G, Tscherter A, Platania P, Wu B, Pothos EN, Shen J.

J Neurochem. 2009 Jul;110(2):613-21. doi: 10.1111/j.1471-4159.2009.06152.x. Epub 2009 May 5.

11.

Pael-R transgenic mice crossed with parkin deficient mice displayed progressive and selective catecholaminergic neuronal loss.

Wang HQ, Imai Y, Inoue H, Kataoka A, Iita S, Nukina N, Takahashi R.

J Neurochem. 2008 Oct;107(1):171-85. doi: 10.1111/j.1471-4159.2008.05607.x. Epub 2008 Aug 7.

12.

Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration.

Van Rompuy AS, Oliveras-Salvá M, Van der Perren A, Corti O, Van den Haute C, Baekelandt V.

Mol Neurodegener. 2015 Jun 23;10:23. doi: 10.1186/s13024-015-0017-8.

13.

Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model.

Klein RL, Dayton RD, Henderson KM, Petrucelli L.

Neurosci Lett. 2006 Jun 19;401(1-2):130-5. Epub 2006 Mar 22.

14.

Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's disease.

Rial D, Castro AA, Machado N, Garção P, Gonçalves FQ, Silva HB, Tomé AR, Köfalvi A, Corti O, Raisman-Vozari R, Cunha RA, Prediger RD.

PLoS One. 2014 Dec 8;9(12):e114216. doi: 10.1371/journal.pone.0114216. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0118526.

15.

Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1.

Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, Tong Y, Martella G, Tscherter A, Martins A, Bernardi G, Roth BL, Pothos EN, Calabresi P, Shen J.

Neuron. 2005 Feb 17;45(4):489-96.

16.

Dopamine covalently modifies and functionally inactivates parkin.

LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ.

Nat Med. 2005 Nov;11(11):1214-21. Epub 2005 Oct 16.

PMID:
16227987
17.

Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio).

Flinn L, Mortiboys H, Volkmann K, Köster RW, Ingham PW, Bandmann O.

Brain. 2009 Jun;132(Pt 6):1613-23. doi: 10.1093/brain/awp108. Epub 2009 May 12.

PMID:
19439422
18.

Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress.

Pickrell AM, Huang CH, Kennedy SR, Ordureau A, Sideris DP, Hoekstra JG, Harper JW, Youle RJ.

Neuron. 2015 Jul 15;87(2):371-81. doi: 10.1016/j.neuron.2015.06.034.

19.

[Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].

Hattori N.

Rinsho Shinkeigaku. 2004 Apr-May;44(4-5):241-62. Review. Japanese.

PMID:
15287506
20.

Chronic overload of SEPT4, a parkin substrate that aggregates in Parkinson's disease, causes behavioral alterations but not neurodegeneration in mice.

Ageta-Ishihara N, Yamakado H, Morita T, Hattori S, Takao K, Miyakawa T, Takahashi R, Kinoshita M.

Mol Brain. 2013 Aug 11;6:35. doi: 10.1186/1756-6606-6-35.

Supplemental Content

Support Center